Nanollose
Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. The last earnings update was 97 days ago. More info.
Add to Portfolio Compare Print
- Nanollose has significant price volatility in the past 3 months.
NC6 Share Price and Events
7 Day Returns
1 Year Returns
NC6 Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Nanollose (NC6) | -10.8% | -14.7% | -27.5% | -65.9% | - | - |
| AU Biotechs | 3% | 8.7% | 12.3% | 14.1% | 78.6% | 167.3% |
| AU Market | 3.5% | 3.6% | 5.5% | 5.6% | 20.1% | 9.4% |
1 Year Return vs Industry and Market
- NC6 underperformed the Biotechs industry which returned 14.1% over the past year.
- NC6 underperformed the Market in Australia which returned 5.6% over the past year.
NC6 Value
Is Nanollose undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Nanollose. This is due to cash flow or dividend data being unavailable. The share price is A$0.058.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Nanollose's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Nanollose's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in AUD | A$-0.03 |
| ASX:NC6 Share Price ** | ASX (2019-05-23) in AUD | A$0.06 |
| Global Biotechs Industry PE Ratio | Median Figure of 76 Publicly-Listed Biotechs Companies | 21.12x |
| Australia Market PE Ratio | Median Figure of 542 Publicly-Listed Companies | 16.13x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Nanollose.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ASX:NC6 Share Price ÷ EPS (both in AUD) = 0.06 ÷ -0.03 |
-2.25x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Nanollose is loss making, we can't compare its value to the Global Biotechs industry average.
- Nanollose is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does
Nanollose's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -2.25x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts |
Not available |
| Global Biotechs Industry PEG Ratio | Median Figure of 57 Publicly-Listed Biotechs Companies | 1.27x |
| Australia Market PEG Ratio | Median Figure of 359 Publicly-Listed Companies | 1.45x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Nanollose, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Nanollose's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in AUD | A$0.03 |
| ASX:NC6 Share Price * | ASX (2019-05-23) in AUD | A$0.06 |
| Australia Biotechs Industry PB Ratio | Median Figure of 43 Publicly-Listed Biotechs Companies | 2.89x |
| Australia Market PB Ratio | Median Figure of 1,680 Publicly-Listed Companies | 1.65x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ASX:NC6 Share Price ÷ Book Value per Share (both in AUD) = 0.06 ÷ 0.03 |
2.09x |
* Primary Listing of Nanollose.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Nanollose is good value based on assets compared to the AU Biotechs industry average.
Value checks
We assess Nanollose's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Nanollose has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
NC6 Future Performance
How is Nanollose expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nanollose has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Nanollose's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare Nanollose's earnings growth to the Australia market average as no estimate data is available.
- Unable to compare Nanollose's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| Australia Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 10.2% |
| Australia Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 8.7% |
| Australia Market Earnings Growth Rate | Market Cap Weighted Average | 7% |
| Australia Market Revenue Growth Rate | Market Cap Weighted Average | 3.2% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 0 | -2 | -2 |
| 2018-09-30 | 0 | -2 | -2 |
| 2018-06-30 | 0 | -2 | -2 |
| 2018-03-31 | 0 | -1 | -1 |
| 2017-12-31 | -1 | -1 | |
| 2017-09-30 | -1 | -1 | |
| 2017-06-30 | -1 | -1 | |
| 2016-06-30 | 0 | 0 | 0 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
All data from Nanollose Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | EPS * |
|---|---|
| 2018-12-31 | -0.03 |
| 2018-09-30 | -0.03 |
| 2018-06-30 | -0.03 |
| 2018-03-31 | -0.02 |
| 2017-12-31 | -0.02 |
| 2017-09-30 | -0.02 |
| 2017-06-30 | -0.02 |
| 2016-06-30 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Nanollose will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Nanollose's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Nanollose has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
NC6 Past Performance
How has Nanollose performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Nanollose does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Nanollose's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Nanollose's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Nanollose Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 0.12 | -1.93 | 1.36 | 0.03 |
| 2018-09-30 | 0.12 | -1.83 | 1.24 | 0.01 |
| 2018-06-30 | 0.12 | -1.73 | 1.12 | |
| 2018-03-31 | 0.06 | -1.46 | 0.88 | 0.05 |
| 2017-12-31 | -1.19 | 0.63 | 0.10 | |
| 2017-09-30 | -1.01 | 0.55 | 0.05 | |
| 2017-06-30 | -0.82 | 0.46 | ||
| 2016-06-30 | 0.01 | -0.01 | 0.01 | 0.01 |
| 2015-06-30 | 0.00 | 0.00 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Nanollose has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Nanollose has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Nanollose improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Nanollose's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Nanollose has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
NC6 Health
How is Nanollose's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Nanollose's finances.
The net worth of a company is the difference between its assets and liabilities.
- Nanollose is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Nanollose has no long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Nanollose has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Nanollose Company Filings, last reported 4 months ago.
| Date (Data in AUD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 2.08 | 0.00 | 2.04 |
| 2018-09-30 | 2.08 | 0.00 | 2.04 |
| 2018-06-30 | 3.04 | 0.00 | 2.98 |
| 2018-03-31 | 3.04 | 0.00 | 2.98 |
| 2017-12-31 | 3.77 | 0.00 | 3.80 |
| 2017-09-30 | 3.77 | 0.00 | 3.80 |
| 2017-06-30 | -0.04 | 0.06 | 0.04 |
| 2016-06-30 | -0.01 | 0.02 | 0.01 |
| 2015-06-30 | 0.00 | 0.02 | 0.01 |
- Nanollose has no debt.
- Nanollose currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Nanollose has sufficient cash runway for 1.1 years based on current free cash flow.
- Nanollose has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 69.9% each year.
Financial health checks
We assess Nanollose's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Nanollose has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
NC6 Dividends
What is Nanollose's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
A$2,000 of
Nanollose
shares you are expected to receive
A$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Nanollose's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Nanollose's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.4% |
| Australia Market Average Dividend Yield | Market Cap Weighted Average of 414 Stocks | 4.1% |
| Australia Minimum Threshold Dividend Yield | 10th Percentile | 1.6% |
| Australia Bottom 25% Dividend Yield | 25th Percentile | 2.6% |
| Australia Top 25% Dividend Yield | 75th Percentile | 5.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Nanollose has not reported any payouts.
- Unable to verify if Nanollose's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Nanollose's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Nanollose afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Nanollose has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
NC6 Management
CEO
| COMPENSATION | A$358,147 |
CEO Bio
Mr. Raffaele Germano, also known as Alfie, has been Managing Director of Nanollose Limited since August 9, 2017 and also serves as its Chief Executive Officer. Mr. Germano is responsible for the operations of Nanollose Limited and development of the Nanollose Technologies. He is a creative achiever who strives for the balance of art and science in product and process. He is a 30-year veteran in the global textile industry sector. He served as Vice President and Director positions at GAP Inc, VF Corporation, Liz Claiborne Inc, Fila Inc and Carter's Inc. He worked with Armani and Gucci. He has travelled the world extensively with postings in the USA, Japan and China. He has served as Vice President for Global Manufacturing of Nonee I, LLC since October 2003. He had overseen the operations of overseas manufacturing facilities. Mr. Germano joined Nonee I in 1996 and served as its Product Manager. He spent 24 years in the garment industry as a leader of large scale global product development, sourcing and retail operations. He worked for his family garment manufacturing company. He has been Director of Nanollose Limited since August 9, 2017. He obtained his Fashion Design and Textile Science Diploma from the Bentley College of Technical and Further Education in Perth, Western Australia.
CEO Compensation
- Insufficient data for Alfie to compare compensation growth.
- Alfie's remuneration is about average for companies of similar size in Australia.
Management Team
Wayne Best
Executive Chairman
A$83K
Alfie Germano
CEO, MD & Director
A$358K
Gary Cass
Executive Director of R&D and Executive Director
A$30K
0.9 yrs
Erlyn Dale
Company Secretary
2.9 yrs
Board of Directors
Wayne Best
Executive Chairman
A$83K
Alfie Germano
CEO, MD & Director
A$358K
1.8 yrs
Gary Cass
Executive Director of R&D and Executive Director
A$30K
Winton Willesee
Non-Executive Director
A$21K
Terry Walsh
Non-Executive Director
A$28K
2.8 yrs
Who owns this company?
Recent Insider Trading
- More shares have been bought than sold by Nanollose insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (A$) | Value (A$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 05. May 19 | Buy | Wayne Best | Individual | 02. May 19 | 02. May 19 | 100,000 | A$0.06 | A$6,320 | ||
| 04. Dec 18 | Buy | Wayne Best | Individual | 04. Dec 18 | 04. Dec 18 | 100,000 | A$0.10 | A$9,700 | ||
| 05. Jul 18 | Buy | Wayne Best | Individual | 28. Jun 18 | 28. Jun 18 | 100,000 | A$0.14 | A$13,517 | ||
Management checks
We assess Nanollose's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Nanollose has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
NC6 News
Simply Wall St News
Do Institutions Own Nanollose Limited (ASX:NC6) Shares?
Insider Ownership Of Nanollose The definition of company insiders can be subjective, and does vary between jurisdictions. … Private Company Ownership Our data indicates that Private Companies hold 9.1%, of the company's shares. … Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual.
Simply Wall St - – Full articleDid You Manage To Avoid Nanollose's (ASX:NC6) 46% Share Price Drop?
Investors in Nanollose Limited (ASX:NC6) have tasted that bitter downside in the last year, as the share price dropped 46%. … There is almost always a chance they will need to raise more capital, and their progress - and share price - will dictate how dilutive that is to current holders. … With the share price down 46% in the last year, it seems likely that the need for cash is weighing on investors' minds.
Simply Wall St - – Full articleWhat Kind Of Shareholder Owns Most Nanollose Limited (ASX:NC6) Stock?
The big shareholder groups in Nanollose Limited (ASX:NC6) have power over the company. … Generally speaking, as a company grows, institutions will increase their ownership. … Our analysis of the ownership of the company, below, shows that.
Simply Wall St - – Full articleIs Nanollose Limited (ASX:NC6) A Financially Sound Company?
Nanollose Limited (ASX:NC6), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is NC6 will have to follow strict debt obligations which will reduce its financial flexibility. … Does NC6's growth rate justify its decision for financial flexibility over lower cost of capital.
Simply Wall St - – Full articleWho Really Owns Nanollose Limited (ASX:NC6)?
This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Private Company Ownership Potential investors in NC6 should also look at another important group of investors: private companies, with a stake of 8.97%, who are primarily invested because of strategic and capital gain interests.
Simply Wall St - – Full articleWhat’s Ahead For Nanollose Limited (ASX:NC6)?
Unsuprisingly, this is below the growth rate of the Australian stock market as a whole. … This means it is an attractive growth stock relative to the wider Australian stock market. … ASX:NC6 PE PEG Gauge Feb 11th 18 The biotech industry is trading at a PE ratio of 27.6x, higher than the rest of the Australian stock market PE of 17.06x.
Simply Wall St - – Full articleBreaking Down Nanollose Limited's (ASX:NC6) Ownership Structure
When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … Check out our latest analysis for Nanollose ASX:NC6 Ownership_summary Jan 23rd 18 Insider Ownership Another important group of shareholders are company insiders. … Insider ownership has to do more with how the company is managed and less to do with the direct impact of the magnitude of shares trading on the market.
Simply Wall St - – Full articleShould You Invest In The Healthcare Stock Nanollose Limited (ASX:NC6)?
However, this rate came in below the growth rate of the Australian stock market as a whole. … In the previous year, the industry saw growth of 9.22%, beating the Australian market growth of 5.37%. … ASX:NC6 PE PEG Gauge Nov 7th 17 The biotech industry is trading at a PE ratio of 27x, higher than the rest of the Australian stock market PE of 17x.
Simply Wall St - – Full articleWho Owns Nanollose Limited (ASX:NC6)?
This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … Such level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Private Company Ownership Another important group of owners for potential investors in NC6 are private companies that hold a stake of 3.60% in NC6.
Simply Wall St - – Full articleNC6 Company Info
Description
Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. It focuses on the development of Nullarbor, a plant-free viscose-rayon fibre; and a commercial supply chain of microbial cellulose from various waste streams. Its products are used in textile, clothing, and other industries. Nanollose Limited has a collaborative research agreement with Umeå University, MoRe Research, and RISE Processum. The company was founded in 2014 and is based in Nedlands, Australia.
Details
| Name: | Nanollose Limited |
| NC6 | |
| Exchange: | ASX |
| Founded: | 2014 |
| A$4,874,999 | |
| 74,999,993 | |
| Website: | http://www.nanollose.com |
| Address: |
Nanollose Limited CPC, Suite 5, Nedlands, Western Australia, 6009, Australia |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ASX | NC6 | Ordinary Shares | Australian Securities Exchange | AU | AUD | 18. Oct 2017 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/23 10:36 |
| End of day share price update: | 2019/05/23 00:00 |
| Last earnings filing: | 2019/02/15 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
